AKBA Akebia Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1517022 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-12.4%
TTM net income YoY-180.2%
TTM EPS YoY-112.5%
Revenue 3-yr CAGR0.5%
Net income 3-yr CAGR—
Margins
Gross margin78.9%
Operating margin-15.7%
Net margin-22.6%
FCF margin7.0%
EBITDA margin-15.1%
Returns
ROE-143.8%
ROA-12.6%
ROIC (approx.)—
Asset turnover0.56x
Leverage & solvency
Liabilities / assets94.0%
Debt / equity2.47x
Current ratio1.36x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.35x
Accruals ratio-17.1%
Payout ratio—
Capex / revenue1.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $36.90M | $49.13M | $53.54M | $57.62M | $58.77M | $62.47M | $57.34M | $46.50M |
| Cost of revenue | $6.36M | $10.42M | $12.29M | $12.54M | $9.38M | $9.92M | $7.62M | $20.36M |
| Gross profit | $30.54M | $38.70M | $41.25M | $45.09M | $49.38M | $52.55M | $49.71M | $26.13M |
| R&D expense | $16.18M | $14.06M | $14.81M | $26.65M | $14.94M | $11.01M | $9.75M | $11.79M |
| SG&A expense | $23.53M | $28.17M | $30.44M | $26.09M | $29.09M | $26.55M | $25.74M | $27.68M |
| Operating income | -$11.46M | -$6.33M | -$4.70M | -$8.55M | $4.45M | $14.09M | $13.51M | -$14.31M |
| Pretax income | -$14.18M | -$8.84M | -$8.93M | -$11.23M | $1.16M | $247,000 | $6.11M | -$22.80M |
| Income tax | $175,000 | $70,000 | $126,000 | $1.01M | $615,000 | $0 | $0 | $0 |
| Net income | -$14.35M | -$8.91M | -$9.05M | -$12.24M | $540,000 | $247,000 | $6.11M | -$22.80M |
| EBITDA | -$11.36M | -$5.74M | -$4.37M | -$8.23M | $4.77M | $14.40M | $13.83M | -$13.97M |
| EPS (basic) | -0.05 | -0.03 | -0.03 | — | 0.00 | 0.00 | 0.03 | — |
| EPS (diluted) | -0.05 | -0.03 | -0.03 | — | 0.00 | 0.00 | 0.03 | — |
| Weighted avg. shares (diluted) | 276.86M | 269.60M | 267.05M | — | 274.37M | 271.10M | 241.60M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $159.25M | $155.55M | $162.64M | $184.84M | $168.14M | $139.00M | $115.06M | $53.55M |
| Receivables | $36.44M | $53.51M | $62.54M | $47.03M | $66.22M | $72.81M | $61.54M | $34.37M |
| Inventory | $18.70M | $13.02M | $13.00M | $15.61M | $18.64M | $16.71M | $19.73M | $16.24M |
| Current assets | $220.78M | $229.55M | $243.48M | $252.96M | $258.34M | $234.66M | $203.78M | $113.83M |
| PP&E, net | $2.40M | $1.51M | $956,000 | $1.22M | $1.47M | $1.71M | $1.90M | $2.20M |
| Goodwill | $59.04M | $59.04M | $59.04M | $59.04M | $59.04M | $59.04M | $59.04M | $59.04M |
| Intangibles | — | — | — | — | — | — | — | $0 |
| Total assets | $342.13M | $349.66M | $362.52M | $376.56M | $364.15M | $345.60M | $310.19M | $220.67M |
| Current liabilities | $162.35M | $160.87M | $173.88M | $162.94M | $133.38M | $118.72M | $91.23M | $80.91M |
| Short-term debt | $37.49M | $24.81M | $12.49M | $0 | — | — | — | $0 |
| Long-term debt | $12.78M | $24.75M | $36.40M | $48.25M | $47.64M | $47.06M | $46.51M | $38.69M |
| Total debt | $50.27M | $49.56M | $48.89M | $48.25M | $47.64M | $47.06M | $46.51M | $38.69M |
| Total liabilities | $321.76M | $324.64M | $335.14M | $343.95M | $322.56M | $316.37M | $285.60M | $269.86M |
| Shareholders' equity | $20.37M | $25.02M | $27.38M | $32.61M | $41.59M | $29.22M | $24.58M | -$49.19M |
| Net debt | -$108.98M | -$105.98M | -$113.75M | -$136.59M | -$120.50M | -$91.94M | -$68.55M | -$14.86M |
| Shares outstanding | 277.52M | 271.74M | 267.90M | 265.42M | 265.23M | 263.04M | 261.64M | 224.85M |
| Cash flow statement | ||||||||
| Operating cash flow | $2.33M | $3.52M | -$21.21M | $31.13M | $28.11M | $22.34M | -$13.59M | -$4.47M |
| Capital expenditure | $706,000 | $1.08M | $62,000 | $70,000 | $77,000 | $126,000 | $18,000 | $2,000 |
| Free cash flow | $1.63M | $2.45M | -$21.27M | $31.06M | $28.03M | $22.22M | -$13.61M | -$4.47M |
| Investing cash flow | -$2.61M | -$4.08M | -$62,000 | -$7.88M | -$77,000 | -$126,000 | $154,000 | -$2,000 |
| Financing cash flow | $3.18M | -$6.54M | -$926,000 | -$4.85M | $1.11M | $1.72M | $74.94M | $22.32M |
| Depreciation & amortization | $101,000 | $585,000 | $328,000 | $321,000 | $318,000 | $316,000 | $314,000 | $335,000 |
| Stock-based compensation | $2.80M | $3.23M | $3.67M | $3.20M | $3.22M | $2.68M | $2.19M | $1.70M |
Free plan shows the latest 8 periods; Pro shows all 55 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.